peptide,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM,netmhcpan_ba_BAV,ann_BAV,smmpmbec_BAV,smm_BAV,mhcflurry_BAV,netmhcpan_ba_BAV_Normalized,ann_BAV_Normalized,smmpmbec_BAV_Normalized,smm_BAV_Normalized,mhcflurry_BAV_Normalized,VTAPERNet_BAV_Normalized,VTAPERNet_BAV
VVGAAGVGK,Positive,=,11230.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1380281737223408,59.83,147.74,102.33636812979309,117.57094257962468,48.52,0.6218492560705053,0.5383034808302579,0.5722402998646032,0.5594140847697237,0.641214821410046,0.3683540225028991,929.1492948112624
VVGACGVGK,Positive,=,29080.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0500908926704839,72.99,134.97,104.23894326174305,119.2065173132749,51.66,0.6034740885915133,0.5466586835158486,0.5705377991053692,0.5581372092002981,0.6354191662733601,0.343714952468872,1213.008244445033
VVGASGVGK,Positive,=,12710.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.126586135521855,50.69,114.36,80.17334432591531,91.68536114619248,52.78,0.6371710630946423,0.5619733378194245,0.5947984349244542,0.5823978450193829,0.6334368203468832,0.282209038734436,2359.8162986788275
VVGAVGVGK,Positive-High,=,5071.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2115094143761372,38.76,65.47,68.0816386199307,82.66087535038571,42.77,0.6619719285475261,0.6135233169723948,0.6099081291626562,0.5919744117900745,0.6528730235026693,0.399594098329544,662.6578122913561
VVVGAAGVGK,Positive-High,=,7030.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1813194548017949,104.17,243.11,61.49361153274806,84.30435305540806,37.47,0.5705989477907696,0.4922711102383082,0.6193144458574241,0.5901548641036434,0.6651002897141998,0.3836605548858642,787.3368259377411
VVVGACGVGK,Positive,=,15630.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1074727069657454,122.12,278.8,89.50143530311811,102.52977397953616,40.12,0.5559054870107658,0.4796109004378503,0.5846259928880307,0.5720657935367819,0.6587846011213385,0.3252450227737427,1481.3353891276834
VVVGADGVGK,Positive,=,15030.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1110905205326742,194.2,429.98,105.88391726063614,115.57130041198332,46.96,0.5130317445183769,0.4395690432293829,0.5690906734600202,0.5609995386017606,0.6442352075674126,0.3254696726799011,1477.7391356362527
VVVGARGVGK,Positive,=,46140.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.0074255451979363,162.14,308.51,90.95571663684504,103.71701280761008,44.33,0.5297075387495429,0.4702521523948814,0.5831363047237008,0.5710017305622606,0.6495619827792413,0.3531599342823028,1095.1713308480169
VVVGASGVGK,Positive,=,10230.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1466479611463769,79.28,213.1,53.19000118548209,73.4260219860633,37.79,0.5958340573094214,0.5044481136152221,0.632721639336392,0.6029236197978984,0.6643143304891337,0.3955666720867157,692.1720803498803
VVVGAVGVGK,Positive-High,=,6954.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1823240661673129,68.99,137.28,46.113703199347285,71.2606861926609,35.83,0.6086831490199263,0.5450902498777108,0.6459160202204559,0.6056901835316537,0.6692367036325164,0.3938205242156982,705.3735555746848
TVLEFILQK,Positive,,2.2,nM,HLA-A*11:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9271281407401551,7.22,9.68,8.433930152776446,9.644950431350724,21.78,0.8172924711633792,0.7901933069590426,0.8029291527408141,0.7905285628357432,0.7152444313998492,0.7945382595062256,9.235460509404536
TVLEFILQK,Positive,,365.0,nM,HLA-A*30:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.4547118066103647,416.12,631.22,433.9203318627721,411.1213208688789,48.3,0.4425972952798446,0.404086268200349,0.4387259340735724,0.4437142612981282,0.6416348414231983,0.5744020938873291,99.97048400285492
GEYAPFARV,Positive,,107.0,nM,HLA-B*40:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.5681215722142137,145.34,134.63,232.87882436455791,137.68923912009654,68.41,0.5398172037995816,0.5468917988777116,0.496244922224294,0.5448151407592919,0.6094634380021205,0.3819728195667267,801.8463981559665
LEHGLYPQL,Positive,,14.0,nM,HLA-B*40:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.7560895186347992,23.5,17.7,39.82263562236151,41.773416872487694,38.93,0.708219490440124,0.7344155708144067,0.6594721825158566,0.6550520649196956,0.6615674494089743,0.7016898393630981,25.220314433352204
EVASFKQAL,Positive,,2.7,nM,HLA-A*68:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9082003580016594,21.12,16.22,57.49631351906263,46.62190338013607,32.76,0.7180884507372038,0.7424859386719747,0.6255264455026792,0.6449030322687114,0.6775157339395478,0.7531213760375977,14.456902388215145
QLSAIALGV,Positive,,11.0,nM,HLA-A*68:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.7783785203571697,186.55,98.81,241.9023013141013,270.7634256029972,116.89,0.5167461696326109,0.5754812443037767,0.4927313862824249,0.4823142097618612,0.5599509346249802,0.6875512599945068,29.389165678881557
ILDTAGKEEY,Positive,,260.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4860632551937173,156.86,324.9,269.4883528866061,327.9442344321343,39.69,0.5327673493024765,0.4654680261786642,0.4827504755814155,0.4646060737398789,0.6597805269171828,0.4523535966873169,374.4329177569532
ILDTAGLEEY,Positive,,329.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4643090090749232,43.85,66.03,161.26495510105232,243.6688423459584,36.16,0.6505681891591314,0.6127361324728979,0.530207684245064,0.4920588984825275,0.6683893661024745,0.5408979654312134,143.65035029535326
ILDTAGHEEY,Positive,,239.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4938469709843969,78.06,185.91,204.89907602901525,265.3383352382341,36.37,0.5972673702536995,0.5170637929641345,0.5080751743750216,0.4841848324710701,0.667854168123116,0.5046162009239197,212.712794180418
ILDTAGREEY,Positive,,246.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4911788956096505,143.44,322.23,269.4883528866061,297.7145087710596,41.1,0.541033402093642,0.4662306911963827,0.4827504755814155,0.4735442027258575,0.6565541341215455,0.5734330415725708,101.02418197110482
ILDTAGQEEY,Positive,,278.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4798764849184373,85.26,86.69,215.5460159641296,284.97056273411505,36.98,0.589113076582847,0.5875757876378922,0.5033932972871281,0.4775876420290382,0.6663168938349685,0.5171462297439575,185.74425193706924
LIVKTVLEF,Positive,,109.0,nM,HLA-A*23:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.5664099800465701,1013.39,726.08,615.4177243526453,934.178784292004,314.2,0.360332878983898,0.3911464700636859,0.4064294946709027,0.3678550837185578,0.468563072673451,0.4050666987895965,624.5593824958407
GLYPQLSAI,Positive,,6.9,nM,HLA-A*02:06,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.821482348267131,31.75,29.11,136.76343494988217,131.68915167332003,25.18,0.6804100200166746,0.6884333792112203,0.5454386816623615,0.5489330644706891,0.7018376953930315,0.760177731513977,13.394226724771748
QLSAIALGV,Positive,,12.0,nM,HLA-A*02:06,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.7703366386565992,84.14,51.74,88.0988014409983,71.37563746317396,25.34,0.5903352211432158,0.6352761514121019,0.586085887289074,0.6055412147152206,0.701252272465658,0.7383935451507568,16.954339847237843
KLVVVGAVGV,Positive,=,35810.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0308505232402733,174.89,300.18,102.75903093107507,156.12771368448506,52.25,0.5227113653241957,0.472781960518789,0.5718593653197246,0.5331998293294178,0.6343695973377759,0.3856943249702453,770.200755794651
LLVVGAAGV,Positive,=,17540.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.096817050308088,48.88,91.02,81.1764397428534,78.54345477051372,25.55,0.640531606782798,0.5830710071861361,0.5936492469119712,0.5966967232710001,0.7004894895749392,0.348747968673706,1148.7188837160293
LLVVGARGV,Positive,=,23700.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0689984524324982,495.02,971.35,270.6636910435053,256.51336624828014,103.74,0.4265503411717048,0.3642488158564237,0.4823482597770464,0.4873110494902135,0.5709812486997505,0.1627460867166519,8594.705984378854
LLVVGAVGV,Positive,=,25560.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0620155384224109,50.85,123.99,79.69480273923205,78.90599488547507,25.32,0.6368797937240996,0.5545009527471598,0.5953517476712051,0.5962710980811915,0.7013252478627745,0.2837466597557068,2320.8814710353263
LLVVVGARGV,Positive-High,=,6550.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1878557861679665,383.56,613.84,374.8176211436028,484.7077904917272,290.06,0.4501277285082787,0.4066667413028871,0.4522586869835339,0.428496032636525,0.4759515722885126,0.2019320279359817,5624.675371205918
YLVVGAAGV,Positive,=,16410.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1029718050629049,11.34,14.33,21.79867015818036,20.85018918905801,12.93,0.7755650592398475,0.7539362478733834,0.7151652386023,0.71927677793585,0.7634378334284628,0.4563482701778412,358.594125979598
YLVVGACGV,Positive,=,26090.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0601186908993082,12.57,18.46,23.19690265540236,23.5564585659527,13.57,0.7660476068858632,0.730529946877408,0.7094192985398853,0.7079977104059245,0.7589727436832672,0.4173461496829986,546.8559799504776
YLVVGADGV,Positive,=,13420.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1215622759830237,22.45,28.45,41.824427020682926,40.37476429813407,16.47,0.7124441432712926,0.6905529787614473,0.6549392742443962,0.6581995631983292,0.7410722779572888,0.341433435678482,1243.3246145074247
YLVVGARGV,Positive,=,15600.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1076502734673309,77.56,102.59,72.68252393851051,68.09418087637532,25.37,0.5978612762662909,0.572011519979865,0.6038642514673754,0.6098911041550636,0.7011429172933896,0.233479157090187,3998.144152899996
YLVVGASGV,Positive,=,21170.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0794321193734345,22.67,20.62,33.996170603489375,32.144746116854755,13.43,0.7115428447349608,0.7203028196105263,0.6740924077857792,0.6792680100938503,0.759931216494727,0.377888560295105,838.075209953112
YLVVGAVGV,Positive,=,22950.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0719705199545163,11.1,16.96,21.400799588364688,20.946429289619577,13.21,0.7775421043713674,0.7383626950616347,0.7168677393615341,0.7188511527460415,0.7614577627479632,0.4365716874599457,444.1531435392008
YLVVVGAAGV,Positive,=,27740.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0544509855058985,58.75,65.58,37.30954906051542,49.258365851146,37.16,0.6235328445784065,0.6133681613934748,0.665496907077596,0.6398189393764491,0.6658681149543833,0.4247980117797851,504.49502641178896
YLVVVGADGV,Positive-High,=,5683.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.2009785862475908,82.77,140.49,87.86582679744987,134.42498602520783,68.36,0.5918524797074438,0.542954006831288,0.5863306217732138,0.5470326479981944,0.6095310137422417,0.3108029663562774,1731.8735845063904
YLVVVGASGV,Positive,=,10650.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.142929279382826,84.01,108.99,62.20424167268146,86.59244451474603,41.2,0.5904781296894885,0.5664184596406533,0.6182525110088517,0.5876798536249068,0.6563295329523335,0.411801666021347,580.6659072505075
YLVVVGAVGV,Positive,=,15470.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1084236950154021,59.19,79.21,38.53186233606172,61.02109547446375,39.06,0.622843231955834,0.5959156982194591,0.6625175307489366,0.6200273680503534,0.6612593318359024,0.4885988533496856,252.9639582702335
YVVVGAVGV,Positive,=,28260.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0527345027941913,110.47,196.35,178.82572728599598,179.93265987039874,32.65,0.5651718669999891,0.5120141427822436,0.5206545268598122,0.5200841891054686,0.6778265908881855,0.2436016052961349,3583.384147123202
EAAGIGILTV,Positive,,22500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.0738007448237922,6687.84,5322.6,1844.250882727236,2220.6494164111296,3740.17,0.1859309867999332,0.2070339188819874,0.3049923713097907,0.2878269074048133,0.2396437221107622,0.1738149374723434,7624.63093579223
SLLMWITQC,Positive,,4450.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2235830389182367,422.15,666.69,308.6242162128781,270.46433212139846,332.12,0.4412675988170673,0.3990334183066961,0.4702179418675041,0.4824163598074157,0.4634366623058533,0.3525615930557251,1102.284381599444
EAAGIGILTVI,Positive,,30700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),11,0.0450804386202429,26676.51,15887.41,2993.505083561932,1794.36173794707,20103.01,0.0580639996512172,0.1059629877454506,0.2602251138457315,0.3075269693150999,0.0842118411653382,0.1411539018154144,10856.555420991668
ELAGIGILTV,Positive,,2480.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2776179295262677,215.85,253.92,124.11377924071788,145.70686026964728,83.55,0.5032630447016206,0.4882502107500545,0.5544087325375758,0.5395842071765453,0.5909855878084099,0.3238009512424469,1504.6623256742234
EMAGIGILTV,Positive,,3600.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2431740365472272,190.98,233.52,147.17024064056125,172.3772706532325,74.01,0.5145770483957455,0.4959908065396109,0.5386606005146611,0.5240488877485349,0.6021914584505768,0.3820825219154358,800.8952071142264
EIAGIGILTV,Positive,,3350.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2498260674607251,1338.13,1929.12,729.1552380615279,871.9267466519077,588.36,0.3346417822367573,0.3008341741836986,0.390755847056205,0.3742288209359402,0.4105850565681227,0.251369833946228,3294.5089721520194
EVAGIGILTV,Positive,,4210.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2287071225201845,2083.09,3152.47,1085.9754311778763,1313.6509977029812,822.93,0.2937371315407521,0.2554430100342917,0.3539392681377691,0.336348179042983,0.3795740572564252,0.1593348383903503,8917.854413562434
ELAGIGILTL,Positive,,4170.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2295894522345869,869.61,819.39,396.1138247863702,479.1593862949253,236.9,0.3744747205187503,0.3799724925368749,0.4471511847058319,0.4295600956110461,0.4946626476586118,0.2623637020587921,2925.033458070376
ELAGIGILTA,Positive,,5610.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.202173485296401,1541.67,1597.3,801.3458644824315,978.3179005429128,459.66,0.3215552730858633,0.3182790082285006,0.3820305306651304,0.3635881911907275,0.4333999343969997,0.2012452334165573,5666.627814311326
ELAGIGILTI,Positive,,2930.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2622069055229073,1040.47,905.68,463.2548768622114,561.6684119737977,256.87,0.3578955473481291,0.3707185245579224,0.4326799282523428,0.4148760265626525,0.487182641409987,0.2741301953792572,2575.374783107141
ELAGIGILTM,Positive,,36800.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.0283300777701626,2573.38,2143.78,792.172934224647,949.4672736115788,1146.3,0.2742018105660914,0.2910828943660291,0.3830945936396517,0.3663547549244828,0.3489427918064862,0.2110676169395446,5095.298170410801
EMAGIGILTL,Positive,,4380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2250484452669637,740.33,875.43,469.6993941486398,566.8654658026629,275.64,0.3893501457178953,0.3738582236958643,0.4314030526829172,0.4140247761830357,0.4806644351866894,0.297690749168396,1995.8601336374809
EMAGIGILTA,Positive,,3620.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2426619945968299,1220.25,1796.83,950.2108825762632,1157.3907310520633,465.18,0.3431648183579573,0.3073999223263844,0.3662823986422157,0.348052871762717,0.4322966454581368,0.2414909750223159,3666.157819502618
EMAGIGILTI,Positive,,1790.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.3077519056350024,878.6,980.84,549.3131554192361,664.4770719031636,281.72,0.3735241560995515,0.3633502308166713,0.4169317962294281,0.3993407071346421,0.4786479425364066,0.3243292272090912,1496.0864657924512
EMAGIGILTM,Positive,,37500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.0265885367416714,2293.04,2397.96,939.3339085474654,1123.2592404835714,1461.42,0.2848620809309431,0.2807270675689852,0.3673464616167369,0.3508194354964724,0.3264960100642491,0.2499372810125351,3345.9713493269114
SLLMWITQA,Positive,,1090.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3535973851423163,17.12,25.68,37.53444512185601,38.38044448454869,20.57,0.7374948639376486,0.7000204261580519,0.6649414662048962,0.6628814402862229,0.7205272026671963,0.5959394574165344,79.18964016219371
SLLMWITQL,Positive,,1970.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2988960935861278,11.66,15.61,20.390599754832827,20.659033505576502,19.57,0.7729931135038766,0.7460288314330175,0.7213368038545234,0.720128028315467,0.7251332048371933,0.5949704051017761,80.02430615163676
SLLMWITQV,Positive,,1190.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3454848703961633,4.55,6.13,7.575826151340562,7.71098751586351,12.33,0.8599668872008278,0.8324184930332013,0.8128462196633525,0.8112118189344876,0.7678293167249344,0.7166305184364319,21.4557990986881
SLLMWITQM,Positive,,2380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2814218958748952,47.27,52.12,66.90059803314166,69.04146529296976,46.18,0.6436270925846144,0.6345998366756619,0.6115255048839285,0.6086142285856382,0.6457832403600647,0.4725910723209381,300.8006228462519
SLLMWITQI,Positive,,1360.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3331434536762918,11.65,15.96,24.85592901698114,25.76973781504873,17.9,0.7730724128100253,0.7439794495592437,0.7030349206927575,0.6996980192046587,0.7333770954435097,0.5851956009864807,88.95153125296092
SALMWITQA,Positive,,2280.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2853891716904157,2076.59,2252.32,960.3510156161524,988.803511407055,709.77,0.2940259769186036,0.2865180900977762,0.3653013325797071,0.3626028688763211,0.3932462568709539,0.3406893610954284,1253.3746761984607
SALMWITQL,Positive,,1990.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2979625166013703,1299.6,1070.67,521.71100758257,532.2430510364176,373.33,0.337342077136128,0.3552511228654121,0.4216966702293342,0.4198494569055653,0.4526262376796441,0.3365539014339447,1310.7302323207828
SALMWITQV,Positive,,1700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3125197823358424,174.77,251.76,193.83401872470665,198.65980278501863,53.46,0.5227748029533955,0.4890397836782038,0.5132060860381633,0.5109332475245858,0.6322536741400853,0.4691430330276489,312.2345547389355
SALMWITQM,Positive,,11400.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1366395513074301,4685.6,3117.47,1711.7092595314382,1778.7298774473677,2841.21,0.2188149301585942,0.2564748700993433,0.3118853712587395,0.3083356571757364,0.2650509938623514,0.2289447337388992,4199.190409180745
SALMWITQI,Positive,,2030.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2961231855361516,1184.1,1147.56,635.9602918877642,663.9112074331928,296.91,0.3459442434662959,0.3488412569136623,0.4033947870675686,0.399419447794757,0.4737942947703367,0.3523112535476684,1105.2740960560943
SMLMWITQA,Positive,,950.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3663029126508308,12.96,19.02,37.70769624875445,38.20410236027925,18.91,0.7632236425199761,0.7277678913844967,0.6645158410150876,0.6633070654760315,0.7283039628542083,0.6434183716773987,47.37687112877508
SMLMWITQL,Positive,,1340.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3345127133224426,8.82,11.53,20.48471848695184,20.56411386869753,18.56,0.7987923769976442,0.774029349769229,0.7209111786647149,0.7205536535052757,0.7300306299652368,0.6262303590774536,57.06007408904834
SMLMWITQV,Positive,,1010.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3606425725190039,3.75,4.88,7.6107945760407345,7.67555874642052,11.71,0.8778389163586858,0.8534955912960788,0.8124205944735439,0.8116374441242962,0.7725976343568182,0.7448301315307617,15.813775095690806
SMLMWITQM,Positive,,1570.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3198723019171888,34.5,36.06,67.20939716316188,68.72424857450943,40.65,0.6727327278841455,0.6686453156862838,0.61109987969412,0.6090398537754467,0.6575716490113128,0.5182018280029297,183.634872743879
SMLMWITQI,Positive,,710.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3932163120666763,9.17,11.86,24.97065877249821,25.651336624827973,16.95,0.7951956844197802,0.7714212501809712,0.702609295502949,0.7001236443944674,0.7384172060249644,0.613608717918396,65.40953239728101
SILMWITQA,Positive,,1920.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3012721456672733,166.01,206.55,202.03657612610988,211.8897750948691,72.16,0.5275274693131469,0.5073334800655476,0.5093754593298868,0.5049744948672666,0.6045310945123878,0.4963279068470001,232.66982208222825
SILMWITQL,Positive,,5420.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2053579224611342,82.74,95.07,109.75643695410538,114.0538631577404,54.03,0.591885984632823,0.5790474312275447,0.565770796979514,0.5622210828965108,0.6312734565361365,0.4694416522979736,311.2273546784782
SILMWITQV,Positive,,1060.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3561768084339461,13.55,22.19,40.77838294863293,42.57062242083815,19.29,0.7591090613121776,0.7135207713626968,0.657280212788343,0.6533048735155313,0.7264651133210401,0.6149751543998718,64.44959615740363
SILMWITQM,Positive,,3100.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2569942581858182,622.51,408.29,360.10570353508774,381.1623536313401,320.65,0.4053704684746666,0.4443529665582212,0.4559594980089192,0.450707283166682,0.4666849879993288,0.37761390209198,840.5694565915164
SILMWITQI,Positive,,2700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2697625732888986,73.17,99.52,133.7919550621074,142.26890863868596,48.02,0.603246444792569,0.5748195103388289,0.5474689138177482,0.5417910737857026,0.6421721879115081,0.4512620866298675,378.88114674236704
GILGFVFTL,Positive,,1020.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3597319904179632,7.27,15.71,45.75409820495877,48.65304206329171,19.96,0.8166546264257808,0.7454386420989727,0.6466395830431302,0.6409617430110846,0.7233094623392751,0.6924877762794495,27.860616048542685
GILGFVFTL,Positive-High,,7048.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1810831114365163,7.27,15.71,45.75409820495877,48.65304206329171,19.96,0.8166546264257808,0.7454386420989727,0.6466395830431302,0.6409617430110846,0.7233094623392751,0.6924877762794495,27.860616048542685
LLAAPSAMA,Positive-Intermediate,,37120.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0275298707312079,244.5,385.15,354.3480115264533,320.7081525234572,91.08,0.4917441777121726,0.4497453910513778,0.4574491861732488,0.4666682277845011,0.5830101021851536,0.3232607841491699,1513.4820551572377
AAVTSQFPV,Positive-Intermediate,,27710.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0545509927318653,722.7,384.47,384.0873466234181,389.143696525184,407.68,0.391577717653044,0.4499087129104614,0.4500007453516,0.4487919698125439,0.4444911536122723,0.2465845346450805,3469.578136956512
LMAVEEREV,Positive-Intermediate,,34110.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0353456788988569,518.17,822.74,330.69680573592444,291.816604622462,175.95,0.4223261133962037,0.3795953986357429,0.4638335640203763,0.4753935441755755,0.522152882631884,0.3562937080860138,1058.6601295157786
GLMKGGANL,Positive-Intermediate,,16990.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.099761570096086,51.79,64.73,154.67851715411774,142.92559208409853,61.11,0.6351868793722757,0.6145739161248709,0.5340617203387801,0.5413654485958939,0.6198928101112212,0.4468584954738617,397.37023933573465
MLREQLDQV,Positive-Intermediate,,13870.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1185139600271665,25.47,113.02,98.27204644097138,96.85231369601692,20.17,0.7007793317118032,0.5630626922352535,0.5759858015349182,0.5773307771347127,0.7223421522144564,0.5201030373573303,179.89596924157854
TLHGFVNHI,Positive-Intermediate,,10650.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.142929279382826,82.98,139.19,306.4996620523416,313.4079437098964,21.92,0.5916182847044771,0.5438132116486036,0.4708563796522168,0.4687963537335433,0.7146522432415916,0.5532380938529968,125.69580858262758
RILSCLSDL,Positive-Intermediate,,29320.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0493312445393411,375.69,478.47,476.9029402520128,475.4556361697735,128.4,0.452043823875159,0.4296931646100647,0.4299963614306002,0.4302772740558734,0.5512708057750664,0.4876436591148376,255.5918946654905
GLLHKVKEL,Positive-Intermediate,,30140.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0467819024498046,334.62,254.9,300.90541275620734,280.61443004119224,91.12,0.4627435602811571,0.4878941910144634,0.4725588804114506,0.4790113582889473,0.5829695211370168,0.4773116111755371,285.8229259150653
ALLVVSREL,Positive-High,,5522.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.2036347542439748,237.39,286.87,185.11005080083555,164.8579898154117,135.24,0.4944716782070982,0.47697364930085,0.5174623379362482,0.5281710677118303,0.546473980440983,0.4958817660808563,233.79566798229595
WLAKTRVFL,Positive-High,,5871.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1979706027278215,44.27,188.5,233.57695902997213,217.8261422038786,42.07,0.6496871611310808,0.5157850864248449,0.4959682658509186,0.5024207437284155,0.6543981956644838,0.3421535491943359,1233.6749312561396
ILCKDLSTV,Positive-High,,9327.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1551889088247557,36.13,55.48,61.15472252437344,63.54918716212552,25.3,0.668466076580509,0.6288257956973913,0.6198251960851944,0.6162754820021912,0.7013982809251655,0.5998254418373108,75.92909880409925
FLTDVACRV,Positive-High,,5380.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.2060425428926392,4.65,5.24,9.25614181717605,10.259117407454506,12.27,0.8579576051189823,0.8469172422211768,0.7943315239066824,0.7848230571663601,0.7682801631586789,0.8072294592857361,8.050502487535367
AVLERYLEL,Positive-High,,5962.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1965490377225576,298.0,145.66,339.1798158082386,341.27934139545687,87.72,0.4734556164876241,0.5396139359004188,0.4614926254764295,0.460922287722086,0.5864841398833207,0.4588309824466705,349.0896563929128
MQSLHFAFL,Positive-Intermediate,,47660.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0044298998091865,174.89,224.13,250.8591809650546,237.19744136053072,40.96,0.5227113653241957,0.4997839975654542,0.4893710754088868,0.4945466777169583,0.6568694955532905,0.406193196773529,616.9931703287342
ALEAVRIEL,Positive-High,,5843.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1984124429748287,651.19,710.01,584.0230661097478,587.6381732407568,179.63,0.4012075582324944,0.3932150103387216,0.4112688530790257,0.4106985153246824,0.5202397828003491,0.4331868290901184,460.7210848725079
TLHDIWPEI,Positive-High,,9314.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1553178185997878,36.67,15.05,83.83589402353462,90.17995203964212,20.78,0.66709493601425,0.7494054018554536,0.5906698705833116,0.5839279675767446,0.7195884327830804,0.6001971960067749,75.62430276651982
GLYDVQLTI,Positive-Intermediate,,31720.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0420596057238248,13.11,9.52,40.03409357950166,42.37502817772874,19.0,0.7621600711094546,0.79173373154512,0.658982713547577,0.6537304987053398,0.7278651279380701,0.7873544096946716,9.981946788233785
ALLSNDNAL,Positive-High,,8692.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1617057112487147,156.17,139.41,240.12092074963067,227.0439845966069,150.09,0.5331748003766928,0.543667245115448,0.4934145147120676,0.498590117020139,0.5368449350400573,0.3378421366214752,1292.5874595214923
LLPMSLHWFI,Positive-Intermediate,,38820.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0233911842770331,16.25,7.89,158.42364453109616,125.16416314772412,188.64,0.7423151532787895,0.8090907151180718,0.5318505974777248,0.5536298384402261,0.5157164685769112,0.3948973715305328,697.2027648968619
LLFAKFSFLI,Positive-Intermediate,,19150.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0887005504710117,16.6,20.79,48.95758650966036,45.02772447771864,67.63,0.7403456317205284,0.7195439664191501,0.6403850208788942,0.6481186305777147,0.6105232879255317,0.5531013011932373,125.88198444894024
RQLLFSLLAV,Positive-Intermediate,,24610.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0655161429737021,14.0,50.7,48.95758650966033,46.18277234528978,188.95,0.7560895186347992,0.6371528318418667,0.6403850208788942,0.6457776920337679,0.5155647101061482,0.6480427384376526,45.06471355354891
SLNVDTAFPL,Positive-Intermediate,,45060.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0096146212694522,23.77,33.75,106.61541457291273,124.30253910918108,291.43,0.7071636591724493,0.6747640917569564,0.5684543638012562,0.5542682762249387,0.4755160696861714,0.5260007977485657,168.77496766607723
TLAGHVYEYI,Positive-Intermediate,,48080.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0036189942318516,26.57,25.25,118.25513276303428,121.19368757341174,59.64,0.6968715371462455,0.7015811164657935,0.5588777970305652,0.5566092147688856,0.6221432285921036,0.7392506003379822,16.79784647424979
KLIASILYQA,Positive-Intermediate,,16220.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1040481539592138,22.74,26.27,59.816362559995305,66.4477071903163,46.54,0.7112579013912146,0.6979210185474156,0.6218703251222241,0.6121533020388958,0.6450655404457342,0.7561641335487366,13.98870212553852
FLIHSSTGLI,Positive-Intermediate,,39570.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.0216226011181674,33.25,74.09,115.82971826456809,110.02211770714364,52.14,0.6761435701366734,0.6020916087872294,0.5607931103847036,0.5655473437548646,0.6345643778854144,0.5197568535804749,180.5710568141271
YLQPRTFLL,Positive,,75.0,nM,HLA-A*02:01,I,Literature,2023,Coarse-grained molecular dynamics-guided immunoinformatics to explain the binder and non-binder classification of Cytotoxic T-cell epitope for SARS-CoV-2 peptide-based vaccine discovery.,binding assay,dissociation constant KD,Homo sapiens (human),9,0.6009633469331641,4.3,5.36,12.230099772446508,11.998031560419417,12.3,0.8651899341781183,0.8448245489926672,0.7685811999232677,0.7703518007128708,0.7680544650351719,0.8725740909576416,3.9698173398519776
GLYPQLSAI,Positive,,5.9,nM,HLA-A*02:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8359529831152714,17.77,27.87,103.37844611848703,102.11981044625588,18.81,0.7340507756695317,0.6924566516960546,0.5713039244470246,0.5724360874519149,0.7287940135020176,0.5639951825141907,111.88543613484477
QLSAIALGV,Positive,,3.9,nM,HLA-A*02:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8742140072226278,28.45,54.99,91.29142790373938,86.12118560562682,23.16,0.6905529787614473,0.6296457057448727,0.5827958045718542,0.5881842194748298,0.709566446732779,0.416756272315979,550.3573636467786
APFARVLNL,Positive,,67.0,nM,HLA-B*08:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.6113882827479642,287.24,718.16,312.70152554770675,245.7819581863302,48.55,0.476854520078493,0.3921601522163829,0.4690049100765496,0.4912608512516367,0.641157693560913,0.2729614078998565,2608.149827870802
YPQLSAIAL,Positive,,17.0,nM,HLA-B*08:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.7381449721443496,481.56,690.34,973.0384456847728,1115.7065944255537,63.95,0.4290982059246978,0.3958116277419086,0.3640883007887527,0.3514429763995421,0.615694386823428,0.6631545424461365,38.267201317963526
GEYAPFARV,Positive,,214.0,nM,HLA-B*44:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.5040585976929456,1107.54,542.77,1257.998142930947,1561.7085932653754,243.48,0.3521219719678731,0.4180393080207337,0.3403490558271833,0.3203616969137756,0.4921305539556883,0.3470559120178222,1169.9429478525035
LEHGLYPQL,Positive,,3.4,nM,HLA-B*44:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8868945925273352,3193.19,5962.07,1329.4744640076929,1565.3087033811566,96.67,0.2542568355824908,0.1965479525840948,0.3352415535494811,0.3201488843188711,0.5775049177243222,0.2370613813400268,3846.145275264969
KVKNEVASF,Positive,,158.0,nM,HLA-A*30:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.5320980800206021,731.07,1895.81,1866.164828300688,1834.2562180964767,79.3,0.390513461454122,0.3024439809734596,0.3039006426979318,0.3054946090337646,0.5958107445748682,0.3302393853664398,1403.4115235714178
KVKNEVASF,Positive,,2.9,nM,HLA-A*32:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9015958821885915,94.09,107.23,72.60390836847102,74.80661442145833,36.77,0.5800050933052596,0.5679231184461506,0.6039642733869803,0.6012019659051231,0.6668432383215283,0.4977056682109833,229.22712023497309
QLSAIALGV,Positive,,81.0,nM,HLA-A*32:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.5938503507965411,4431.22,3900.64,12733.85792449674,11666.48427489963,3359.75,0.2239739115304408,0.2357610568478324,0.1264128104218351,0.1345039452800948,0.2495574648580035,0.4544835984706878,365.9023575127587
TVLEFILQK,Positive,,2.2,nM,HLA-A*68:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9271281407401551,49.17,50.76,111.13478150493036,124.59195485826608,25.06,0.6399848888737044,0.6370435197822328,0.5646173527151328,0.5540533355040856,0.7022792089825625,0.6859518885612488,29.902166513139267
CIVYLSLSR,Positive-Intermediate,,39860.0,nM,HLA-A*03:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0209477204325033,1698.01,1331.99,1804.5129371190408,1555.2492479174653,2004.61,0.3126280353774539,0.3350668419952037,0.307005578457585,0.3207447595846033,0.2972864501244154,0.3121816217899322,1706.231390446194
ILRGSVAHK,Positive-High,,9460.0,nM,HLA-A*03:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1538802902055126,28.41,19.94,58.39289402991755,64.09143566447763,36.15,0.6906830151327352,0.7234021173201142,0.6240963448649228,0.6154902035269946,0.6684149291881433,0.4324817359447479,464.2493450358295
TVLEFILQK,Positive,,19.0,nM,HLA-A*03:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.7278651279380701,64.28,63.2,92.54650023611966,82.56576326213263,31.39,0.615218682727728,0.6167847258823196,0.581533825884072,0.5920808180875268,0.6814639560757221,0.3628986775875091,985.643821172464
EVASFKQAL,Positive,,86.0,nM,HLA-A*26:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.5883143647525967,574.33,711.12,571.2286744979199,624.611534579779,52.87,0.412815680967651,0.3930706323811388,0.4133161102420046,0.4050589815597197,0.6332793550895188,0.4673820734024048,318.2406558877877
CWNVEQARF,Positive-High,,1925.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3010317727472659,279.97,368.75,851.0596491020302,572.3082415101953,116.75,0.4792238522400543,0.4537670964875827,0.3764676094343331,0.4131416039141832,0.5600616970675342,0.4634124040603637,332.20718259125493
RVAVILNEF,Positive-High,,2530.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2757730911166582,967.57,1569.41,907.7369206678108,854.338543482408,470.11,0.3646091820926266,0.3199070407812896,0.3705088567770138,0.3761122124008428,0.4313222925520448,0.2940742075443268,2075.5066252637703
KYISTSLPV,Positive-High,,7135.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1799492284703009,131.44,240.27,454.9461561308376,453.55504284176845,94.6,0.5491080920984962,0.4933571514212894,0.4343526352482901,0.4346356759995128,0.57950548001402,0.4066814184188843,613.7425280195968
IWEQLASRF,Positive-High,,6405.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1899247855235927,401.23,94.75,434.4702061439005,433.1417032665245,100.92,0.4459650954583378,0.5793590474473762,0.4386088871463752,0.4388919278975977,0.5735284030337822,0.4630234837532043,333.60806629224004
FFNKGGSVF,Positive-Intermediate,,13260.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1226708150372021,290.57,598.67,1009.1599347312964,1317.1341194590916,77.94,0.4757892110143736,0.4089795224989863,0.3607194774114183,0.3361034445588433,0.5974095600288931,0.2758610248565674,2527.59404309262
LMKGGANLF,Positive-Intermediate,,26720.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0579134470493315,1258.68,821.12,1018.4975766405184,989.988158677964,232.21,0.3402989743287008,0.3797775623871785,0.3598682270318014,0.3624922063269707,0.4965107425068169,0.2376238852739334,3822.8080786329697
LFTKLHPAF,Positive-Intermediate,,19600.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0865538474610913,234.04,490.66,809.0213821238207,854.3385434824045,41.58,0.4957852279856233,0.4273679865973726,0.3811494865222268,0.3761122124008431,0.655480991897882,0.4512068629264831,379.1075989912768
SYYMPQLFW,Positive-Intermediate,,27770.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0543510863763961,41.79,67.36,205.09732685070875,156.9025493305815,71.34,0.6550153821693336,0.6108930091478733,0.5079857930851619,0.5327422822503738,0.6055873727024955,0.5728241205215454,101.69196615466451
EMQSLHFAF,Positive-High,,4845.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2157230673985694,365.9,435.21,628.0005151645744,515.9765923596126,297.74,0.4544841939571351,0.4384516472048877,0.4045588719616948,0.4227181706848744,0.4735362894952911,0.395486056804657,692.7760835434979
KYSDVIKVL,Positive-High,,1376.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3320624666675245,247.58,439.64,837.4521463815693,969.6834870982608,37.29,0.4905871805113359,0.4375156264551491,0.377957297598663,0.3644075196811093,0.6655453467651198,0.4413830637931824,421.6229350091387
DYPGQGFSF,Positive-High,,5841.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.198444083966458,305.51,100.14,54.32002985919668,55.0338632056369,59.94,0.4711552897951069,0.5742455080120088,0.6307786603449161,0.6295720129318088,0.6216794878517587,0.508090615272522,204.86484699651055
RFTLSVPGF,Positive-High,,1597.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3182963685270169,294.69,636.33,610.8857576568441,596.5268551115099,50.46,0.4744879417217382,0.4033410734487065,0.4071126231005457,0.4093109772059063,0.6375913775550504,0.3573301434516907,1046.8546310602471
VYSFLCKTI,Positive-High,,606.9,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.4077176200481553,30.2,55.0,188.78174666745525,152.27548801155638,44.08,0.6850358819929772,0.6296288999741841,0.5156470465017149,0.5355088459841291,0.6500846814671111,0.6677803993225098,36.39904074243972
QYDPVAALF,Positive-High,,707.4,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.393555384935597,66.55,104.98,138.02571323684202,127.53518015983992,31.89,0.6120111304970308,0.5698830665939287,0.5445895594086934,0.5518954157917564,0.6800033799203979,0.5293537378311157,162.76186913359624
HYSPLILAL,Positive,,64.0,nM,HLA-A*24:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.6156221528723917,190.48,314.8,601.1183698856396,637.7199450443057,35.02,0.5148193369412721,0.4683867482912336,0.4086023112648754,0.4031394119536833,0.6713500745222049,0.5969244241714478,78.35018753282279
EPRSPSHSM,Positive,=,27.0,nM,HLA-B*07:02,I,Literature,2023,Molecular mechanism of phosphopeptide neoantigen immunogenicity.,purified MHC/direct/fluorescence,dissociation constant KD (~EC50),Homo sapiens (human),9,0.6953877630974059,19.57,9.73,17.91265659143932,18.53062212293167,42.42,0.7251332048371933,0.7897171424042798,0.7333117685697856,0.7301770390468458,0.6536324635656992,0.5861228108406067,88.06361259047364
LPASPAHQL,Positive,=,54.3,nM,HLA-B*07:02,I,Literature,2023,Molecular mechanism of phosphopeptide neoantigen immunogenicity.,purified MHC/direct/fluorescence,dissociation constant KD (~EC50),Homo sapiens (human),9,0.6308127466257405,27.3,22.85,33.27821321810366,36.46615721545553,31.74,0.694366500378695,0.710811900660795,0.6760651805405413,0.6676101361449955,0.6804391343138587,0.4437998235225677,410.7408955471499
APFARVLNL,Positive,,0.21,nM,HLA-B*07:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,1.1442402706637098,33.14,73.34,105.96440405655926,99.058101443723,35.44,0.6764498384368492,0.6030319614929818,0.5690204453037018,0.5752494699565496,0.6702482221028857,0.6322311758995056,53.47301513666299
YPQLSAIAL,Positive,,44.0,nM,HLA-B*07:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.6502525713146337,15.19,10.54,13.248295305335242,13.928039827995688,32.42,0.7485496241149672,0.7823266354259142,0.7611902185022428,0.7565658008149734,0.6784799628177283,0.498809814453125,226.50492439377905
EVASFKQAL,Positive,,250.0,nM,HLA-B*07:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.4896881643297754,3903.81,5030.47,1746.465456064331,1949.350797154922,1108.86,0.2356859760951563,0.2122510763114991,0.3100275173052256,0.2998699721504453,0.3520118846032481,0.0918806716799736,18502.29001888444
KVKNEVASF,Positive,,5.6,nM,HLA-B*15:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8407761644965167,32.33,59.17,80.34336181471419,78.34296427662125,34.06,0.6787368927193507,0.6228744666082592,0.594602647337142,0.5969329452513437,0.6739190413616837,0.4854975342750549,261.5963340530843
LIVKTVLEF,Positive,,0.8,nM,HLA-B*15:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,1.0206236713404495,25.71,18.59,92.4591720254764,83.36811846196326,45.37,0.6999125179897561,0.7298813594041547,0.5816210790479828,0.591187005188929,0.6474187369280464,0.7589165568351746,13.578252107866025
GLYPQLSAI,Positive,,1.4,nM,HLA-A*02:03,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9689021135390528,3.26,2.65,8.084813386842312,8.202571033045343,12.17,0.8907808307790085,0.9099279472849892,0.8068363919832562,0.8054999288872575,0.769036495821722,1.0263100862503052,0.7522629866551745
QLSAIALGV,Positive,,4.4,nM,HLA-A*02:03,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8630651662188873,9.7,12.99,31.093527879498136,29.17091152137685,14.23,0.7900025466526299,0.763009946851026,0.6823410239642678,0.6882401890950136,0.754583472756763,0.8189812898635864,7.089269544025455
